CEL-SCI Receives Key Chinese Patent for Its Investigational Cancer Therapy Multikine

CEL-SCI Corporation CVM today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine. The patent, Chinese patent number ZL200480025403.6, is titled, “A Method of Pre-Sensitizing Cancer Prior to Treatment with Radiation and/or Chemotherapy and a Novel Cytokine Mixture”.